News und Analysen

On Tuesday, Merck (NYSE: MRK) wasn't one of the better-performing pharmaceutical stocks. In contrast to certain peers, the company's share price declined following the release of second-quarter

Merck (NYSE:MRK), a leading developer of prescription medicines, vaccines, and animal health products, released its second-quarter 2025 results on July 29, 2025. The most notable news was a beat on

Healthcare stocks aren't exactly known for offering large yields, with the average healthcare stock at just 1.8% or so. You can do better than that and get reliable dividend stocks while you are at

Merck (NYSE: MRK), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its

One of the biggest concerns with healthcare giant Merck (NYSE: MRK) is its dependence on top-selling cancer drug Keytruda. While it has been a beast for the business over the years, generating

Most people love a bargain; investors do too. Purchasing shares of companies that can perform well over long periods is already pretty exciting, but it's even more so when they can be scooped up

There are excellent reasons to invest in dividend stocks, including the fact that they typically outperform their non-dividend-paying peers in delivering strong market returns over long periods.

Even when equities are volatile, investors can find great stocks to buy. And the rules for investing in the current environment aren't that different, at least for those focused on the long game

One great thing about a crash or downturn in the markets is that it can allow you to go bargain hunting fairly easily. Many stocks have been falling this year, and if you're a dividend investor, you

The Dow Jones Industrial Average (DJINDICES: ^DJI) fell sharply after the U.S. released a new tariff program. Does that open up some opportunities for investors who like high-yield stocks? A quick

Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key is to purchase shares of robust companies, occasionally adding more, and

Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. While there are concerns about its patent losses in the future, its sales are still

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates with

Most companies don't survive for decades, much less pay regular dividends for that long. However, some rare corporations can pull it off. These are the kinds of stocks long-term investors will often